A multicenter phase Ⅱ study of osimertinib plus infliximab in patients with EGFR-mutated non-small cell lung cancer positive for TP53 gain-of-function mutation who developed resistance to osimertinib (REGAIN trial)

International Journal of Lung Cancer · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles